Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product

Sponsor

Laboratorios Andromaco S.A. (Industry)

Overall Status

Completed

CT.gov ID

NCT04230070

Collaborator

(none)

Enrollment

Location

Arms

Actual Duration (Days)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This Pivotal study will investigate the bioavailability in women of 2 tablet formulations containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The Pivotal study will be performed at a single site with 30 subjects. Participants will take 2 tablets of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There will be a washout of at least 14 days between each study period.

Condition or Disease	Intervention/Treatment	Phase
Bioequivalence	Drug: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug Drug: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product	Phase 1

Detailed Description

The primary objective of the study is to investigate the relative bioavailability of Levonorgestrel and Ethinyl estradiol of 2 tablet formulations with Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg and to demonstrate bioequivalence of both formulations in terms of rate and extent of absorption:

Test Product: Product manufactured by Laboratorios Andrómaco S.A.
Reference Product: Microgynon [Trademark], product of Bayer AG, Germany. The 90% confidence intervals for the intra-subject coefficient of variation (Test versus Reference Product) for the main pharmacokinetic parameters área under the plasma concentration-time curve from time zero to time t (AUC0-t) and from time zero to 72 hours (AUC0-72), and maximum plasma concentration (Cmax) for total Levonorgestrel and Ethinyl estradiol will be determined.

Participants will be confined in the study site for approximately 36 hours during each study period (for 12 hours pre-dosing and for 24 hours post dosing) during which pharmacokinetic (PK) blood samples will be obtained. 16 blood samples will be taken up to 24 hours after the administration in each period. Participants will return to the site to provide additional blood samples at 48 h, and 72 h postdose.

The washout period between the two study periods will be at least 14 days. The samples from each participant will be analyzed with 2 methods of highperformance liquid chromatography-tandem mass spectrometry bioanalytical assays to quantify total Levonorgestrel and Ethinyl estradiol in plasma.

The safety objective is to evaluate the tolerability of both formulations in women by collecting adverse events.

Study Design

Study Type:

Interventional

Actual Enrollment :

30 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

None (Open Label)

Primary Purpose:

Basic Science

Official Title:

Bioavailability of a Formulation of Levonorgestrel and Ethinyl Estradiol 15.0 mg/0.03 mg Coated Tablets With Regards to the Marketed Reference Product

Actual Study Start Date :

Oct 24, 2020

Actual Primary Completion Date :

Oct 31, 2020

Actual Study Completion Date :

Nov 17, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Levonorgestrel and Ethinyl estradiol Test Product Participants will receive two tablets of the test formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.	Drug: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug Bioequivalence Other Names: Investigational Medicinal Product
Active Comparator: Levonorgestrel and Ethinyl estradiol Reference Product Participants will receive two tablets of the marketed reference formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.	Drug: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product Bioequivalence Other Names: Microgynon CD (Trademark)

Arm

Intervention/Treatment

Experimental: Levonorgestrel and Ethinyl estradiol Test Product

Participants will receive two tablets of the test formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.

Drug: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug

Bioequivalence

Other Names:

Investigational Medicinal Product

Active Comparator: Levonorgestrel and Ethinyl estradiol Reference Product

Participants will receive two tablets of the marketed reference formulation containing Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg. The tablets will be taken with water.

Drug: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product

Bioequivalence

Other Names:

Microgynon CD (Trademark)

Outcome Measures

Primary Outcome Measures

Total Ethinyl estradiol: area under the plasma concentration-time curve from 0 to 72 hours (AUC0-72) [From tablet intake and up to 72 hours after tablet intake]
19 samples up to 72 hours will be taken after the administration in each period.
Total Levonorgestrel: area under the plasma concentration-time curve from 0 to 72 hours (AUC0-72) [From tablet intake and up to 72 hours after tablet intake]
19 samples up to 72 hours will be taken after the administration in each period
Total Ethinyl estradiol: area under the plasma concentration-time curve from 0 to time t (AUC0-t) [From tablet intake and up to 72 hours after tablet intake]
19 samples up to 72 hours will be taken after the administration in each period
Total Levonorgestrel: area under the plasma concentration-time curve from 0 to time t (AUC0-t) [From tablet intake and up to 72 hours after tablet intake]
19 samples up to 72 hours will be taken after the administration in each period
Total Ethinyl estradiol: Maximum plasma concentration (Cmax) [From tablet intake and up to 72 hours after tablet intake]
19 samples up to 72 hours will be taken after the administration in each period
Total Levonorgestrel: Maximum plasma concentration (Cmax) [From tablet intake and up to 72 hours after tablet intake]
19 samples up to 72 hours will be taken after the administration in each period
Total Levonorgestrel: Time to achieve maximum plasma concentration (tmax) [From tablet intake and up to 72 hours after tablet intake]
19 samples up to 72 hours will be taken after the administration in each period
Total Ethinyl estradiol: Time to achieve maximum plasma concentration (tmax) [From tablet intake and up to 72 hours after tablet intake]
19 samples up to 72 hours will be taken after the administration in each period

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 55 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Non-pregnant and non-breastfeeding women
Women of childbearing age with an acceptable form of contraception during the study
18 to 55 years old inclusive; BMI greater than or equal to 18.51 and less than or equal to 29.99
Non-smoking or smoke only 3 cigarettes every 7 days
With results of laboratory tests, electrocardiogram and chest radiography in normal and / or negative or abnormal ranges but without clinical relevance and declared suitable for study by the doctor after the physical examination
Capable to understand the Informed Consent Form

Exclusion Criteria:

Study site or sponsor staff or any of their family members
With history of drug and/or alcohol abuse
Smokers more tan 3 cigarettes every 7 days
Vitamin supplements intake 7 days prior to the administration of the medications under study
Any recent change in eating habits or physical exercise
Using of a pharmacological therapy (except over the counter medication use 7 days prior to the study)
Hypersensitivity to the study drug or to other chemically related compounds, history of serious adverse reactions or hypersensitivity to any medication
Use, during the 28 days prior to the start of the study, of medications known to alter liver enzyme activity
Consumption of beverages or food containing grapefruit or pink grapefruit, within 7 days prior to each administration of the study medication and consumption of alcohol, caffeine or beverages or foods containing xanthines 24 hours before each administration of the study medication until the last sample of each period
History of any significant cardiovascular disease
Acute disease that generates significant physiological changes from the time of selection until the end of the study
HIV, Hepatitis B and/or C positive
Presence or history of thrombophlebitis, thrombosis or thromboembolic disorders, deep vein thrombosis, pulmonary embolism or known coagulopathy.
Donation or loss of a significant volume (more than 100 mL) of blood or plasma or platelets during the 3 months prior to the start of the study
Subjects who have participated in any type of clinical study during the 3 months prior to the start of the study
History of any gastrointestinal surgery that could affect drug absorption
Presence of fainting history or fear to blood collection